Your browser is no longer supported. Please, upgrade your browser.
Settings
SGEN Seattle Genetics, Inc. daily Stock Chart
SGEN [NASD]
Seattle Genetics, Inc.
Index- P/E- EPS (ttm)-0.41 Insider Own1.10% Shs Outstand159.08M Perf Week-1.48%
Market Cap10.46B Forward P/E- EPS next Y-0.72 Insider Trans294.21% Shs Float156.52M Perf Month14.69%
Income-62.50M PEG- EPS next Q-0.38 Inst Own98.02% Short Float8.83% Perf Quarter17.98%
Sales513.70M P/S20.36 EPS this Y92.50% Inst Trans14.50% Short Ratio14.35 Perf Half Y26.88%
Book/sh8.41 P/B7.82 EPS next Y60.00% ROA-17.90% Target Price65.67 Perf Year1.91%
Cash/sh2.51 P/C26.16 EPS next 5Y- ROE-22.20% 52W Range45.31 - 69.71 Perf YTD22.90%
Dividend- P/FCF- EPS past 5Y30.30% ROI-7.00% 52W High-5.67% Beta1.88
Dividend %- Quick Ratio3.30 Sales past 5Y18.00% Gross Margin88.70% 52W Low45.11% ATR2.39
Employees1100 Current Ratio3.80 Sales Q/Q28.90% Oper. Margin-44.80% RSI (14)66.20 Volatility4.16% 3.64%
OptionableYes Debt/Eq0.00 EPS Q/Q-74.50% Profit Margin-34.50% Rel Volume0.77 Prev Close65.11
ShortableYes LT Debt/Eq0.00 EarningsJul 26 AMC Payout- Avg Volume962.91K Price65.75
Recom2.40 SMA207.48% SMA5017.41% SMA20017.70% Volume744,772 Change0.98%
Jun-11-18Upgrade SunTrust Hold → Buy
Mar-20-18Resumed Barclays Overweight $74
Feb-14-18Upgrade JP Morgan Neutral → Overweight
Feb-07-18Reiterated Needham Buy $72 → $74
Nov-13-17Reiterated RBC Capital Mkts Outperform $68 → $69
Oct-27-17Upgrade BofA/Merrill Underperform → Neutral
Oct-24-17Resumed Guggenheim Buy $72
Oct-20-17Upgrade Barclays Equal Weight → Overweight $60 → $70
Oct-06-17Resumed Goldman Neutral
Sep-15-17Initiated RBC Capital Mkts Outperform $58
Mar-16-17Initiated Oppenheimer Perform
Feb-10-17Downgrade BofA/Merrill Neutral → Underperform
Dec-12-16Downgrade Credit Suisse Outperform → Neutral
Dec-06-16Reiterated RBC Capital Mkts Outperform $62 → $72
Oct-10-16Reiterated RBC Capital Mkts Outperform $55 → $62
Sep-15-16Upgrade Goldman Sell → Neutral
Sep-07-16Initiated Morgan Stanley Overweight
Jul-27-16Reiterated SunTrust Neutral $34 → $38
Jul-27-16Reiterated RBC Capital Mkts Outperform $125 → $130
Jul-27-16Reiterated Barclays Overweight $48 → $53
Jun-13-18 08:00AM  Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer Business Wire
Jun-07-18 07:35AM  Today's Free Research Reports Coverage on Seattle Genetics and Three More Biotech Stocks ACCESSWIRE
Jun-06-18 08:00AM  Seattle Genetics to Present at the Goldman Sachs 39th Annual Global Healthcare Conference Business Wire
Jun-04-18 09:00AM  Seattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at 2018 ASCO Annual Meeting Business Wire
Jun-03-18 09:00AM  Seattle Genetics and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy Business Wire
09:00AM  Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy PR Newswire
Jun-01-18 12:16PM  3 Biotech Stocks Poised for 12% Gains Investopedia
08:30AM  Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Seattle Genetics ACCESSWIRE
May-28-18 03:23AM  Why Is Seattle Genetics (SGEN) Up 13.3% Since Its Last Earnings Report? Zacks
May-17-18 09:00AM  Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer Business Wire
08:00AM  Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting Business Wire
May-14-18 06:00AM  4 Biotech Stocks Set to Rise By 14% or More Investopedia
May-09-18 07:45AM  Factors of Influence in 2018, Key Indicators and Opportunity within Patterson Companies, Zayo Group, Six Flags Entertainment Corporation New, Leucadia National, Seattle Genetics, and RPC New Research Emphasizes Economic Growth GlobeNewswire
May-04-18 07:30AM  Blog Exposure - Cellectar Receives Rare Pediatric Disease Designation from FDA ACCESSWIRE
May-03-18 09:05AM  The Bothell economy: City looks to Lake Union area as model to build up biotech hub American City Business Journals
May-02-18 04:10PM  Seattle Genetics Accelerates Revenue Growth, Earnings Not So Much Motley Fool
08:00AM  Seattle Genetics to Present at the Bank of America Merrill Lynch Health Care Conference 2018 Business Wire
Apr-27-18 11:50PM  Edited Transcript of SGEN earnings conference call or presentation 26-Apr-18 8:30pm GMT Thomson Reuters StreetEvents +5.57%
12:15PM  Why Seattle Genetics Jumped Higher Today Motley Fool
11:06AM  Seattle Genetics (SGEN) Q1 Earnings Lag Estimates, Sales Top Zacks
05:00AM  Seattle Genetics searches for 10th building in effort to keep up with growth American City Business Journals
Apr-26-18 05:39PM  Seattle Genetics: 1Q Earnings Snapshot Associated Press
04:02PM  Seattle Genetics Reports First Quarter 2018 Financial Results Business Wire
Apr-19-18 05:28PM  Seattle Genetics searches for its 10th building to keep up with growth American City Business Journals
Apr-12-18 08:00AM  Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting Business Wire
Apr-05-18 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 26, 2018 Business Wire
Mar-28-18 05:02PM  Biotech Stock Roundup: PTGX Down, VRNA Up, AMGN's Repatha Gets Positive Opinion Zacks
Mar-26-18 05:53PM  Seattle Genetics wins FDA approval for cancer drug that could push U.S. sales past $1 billion American City Business Journals +5.14%
08:00AM  Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Business Wire
08:00AM  Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer PR Newswire
Mar-23-18 10:28AM  Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus Zacks
Mar-21-18 10:55AM  Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion Zacks
Mar-20-18 02:10PM  Seattle Genetics' Hodgkin's lymphoma drug wins U.S. approval Reuters
12:48PM  Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma Business Wire
Mar-16-18 03:15PM  Seattle Genetics adds second woman to its board with the appointment of Alpna Seth American City Business Journals
Mar-15-18 08:00AM  Seattle Genetics Appoints Dr. Alpna Seth to Board of Directors Business Wire
Mar-13-18 08:00AM  Seattle Genetics to Present at the Barclays Global Healthcare Conference 2018 Business Wire
06:32AM  Is Celldex Therapeutics Stock About to Skyrocket? Motley Fool
Mar-09-18 09:26AM  Seattle Genetics Completes Acquisition of Cascadian Therapeutics Business Wire
06:00AM  Seattle Genetics Completes Tender Offer for All Shares of Cascadian Therapeutics Business Wire
Mar-08-18 10:00AM  Seattle Genetics (SGEN) Up 8.4% Since Earnings Report: Can It Continue? Zacks
Mar-07-18 08:00AM  Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple Myeloma Business Wire
07:45AM  Report: Developing Opportunities within Seattle Genetics, PBF Energy, Chipotle Mexican Grill, CIT Group Inc (DEL), PDL BioPharma, and Dollar General Future Expectations, Projections Moving into 2018 GlobeNewswire
Feb-27-18 08:00AM  Seattle Genetics to Present at Cowen and Company 38th Annual Health Care Conference Business Wire
Feb-16-18 08:00AM  Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period Business Wire
Feb-15-18 07:48AM  Seattle Genetics Inc (SGEN) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com
Feb-14-18 12:14PM  Here's Why Pieris Pharmaceuticals Inc. Is Tanking Motley Fool
08:30AM  PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates PR Newswire
Feb-12-18 07:20AM  Wired News Pieris Pharma Collaborated with Seattle Genetics to Develop Immuno-Oncology Treatments ACCESSWIRE
Feb-09-18 12:50PM  Why Pieris Pharmaceuticals Inc. Is Soaring Today Motley Fool
06:45AM  Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration Business Wire
06:45AM  Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration Marketwired
Feb-08-18 05:39PM  Seattle Genetics Commences Tender Offer for Cascadian Therapeutics, Inc. Business Wire
04:14PM  Seattle Genetics Is Growing Up Any Way It Can Motley Fool
08:10AM  Todays Research Reports on Stocks to Watch: Array BioPharma Inc. and Seattle Genetics ACCESSWIRE
Feb-07-18 10:59AM  Seattle Genetics (SGEN) Q4 Earnings & Revenues Top Estimates Zacks
Feb-06-18 05:55PM  Seattle Genetics reports 4Q loss Associated Press
04:02PM  Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results Business Wire
12:30PM  Seattle Genetics, Inc. to Host Earnings Call ACCESSWIRE
Feb-05-18 09:46AM  The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex Zacks
08:50AM  Why Earnings Season Could Be Great for Seattle Genetics (SGEN) Zacks
Feb-03-18 10:32AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Feb-02-18 08:30AM  Seattle Genetics Announces Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
08:20AM  Todays Research Reports on Trending Tickers: Nektar Therapeutics and Seattle Genetics, Inc. ACCESSWIRE
07:20AM  Wired News Seattle Genetics to Acquire Cascadian Therapeutics ACCESSWIRE
Feb-01-18 04:02PM  Biotech Roundup: Who's Popping On Drug, Merger, Earnings News? Investor's Business Daily +7.36%
08:03AM  Cascadian Therapeutics Scores Big On Seattle Genetics Acquisition Market Exclusive
07:48AM  Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi Zacks
06:30AM  Seattle Genetics Announces Pricing of Public Offering of Common Stock Business Wire
Jan-31-18 03:22PM  Here's Why Cascadian Therapeutics Jumped Up to 73.1% Today Motley Fool -5.27%
11:34AM  Why Cascadian Therapeutics Inc (USA) Is Todays Best Biotech Stock SmarterAnalyst
11:00AM  Why Cascadian Therapeutics Shares Are Skyrocketing 24/7 Wall St.
08:42AM  Benzinga Pro's 6 Stocks To Watch Today Benzinga
06:40AM  Seattle Genetics Announces Proposed Public Offering of Common Stock Business Wire
06:30AM  Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline Business Wire
Jan-26-18 09:30AM  Seattle Genetics Adcetris Performs Well Despite Competition Zacks
Jan-23-18 05:10PM  Key Updates on Novartiss Kymriah Market Realist
03:39PM  How Is Novartiss Kymriah Positioned for 2018? Market Realist
09:44AM  Seattle Genetics' Adcetris Gets EU Nod for Label Expansion Zacks
Jan-22-18 08:00AM  Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy Business Wire +5.25%
Jan-19-18 10:32AM  Opdivo Could Be Long-Term Growth Driver for Bristol-Myers Squibb Market Realist
Jan-18-18 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018 Business Wire
Jan-08-18 07:00PM  Cramer's lightning round: Mercadolibre is even better tha... CNBC Videos
06:50PM  Cramer's lightning round: Mercadolibre is even better than eBay was CNBC
08:08AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
08:00AM  Seattle Genetics Highlights Leadership in Expanding Field of Antibody-Drug Conjugates (ADCs) at the 36th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-05-18 09:48AM  Cancer Space Update: New Regulatory Status for 3 Major Drugs Zacks
08:06AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
Jan-04-18 08:06AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
08:04AM  Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer Zacks
Jan-03-18 01:33PM  Seattle Genetics' Adcetris sBLA Gets FDA Priority Review Zacks
Jan-02-18 08:07AM  See what the IHS Markit Score report has to say about Seattle Genetics Inc. Markit
08:00AM  FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma Business Wire
Dec-28-17 12:40PM  ETFs with exposure to Seattle Genetics, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:44AM  Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-19-17 08:00AM  Seattle Genetics to Present at the J.P. Morgan Healthcare Conference Business Wire
Dec-15-17 08:00AM  Todays Research Reports on Trending Tickers: Juno Therapeutics and Seattle Genetics ACCESSWIRE
Dec-11-17 01:06PM  Why Seattle Genetics, Inc. Fell Today Motley Fool -6.74%
10:30AM  Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed or Refractory Hodgkin Lymphoma Business Wire
Dec-10-17 06:33PM  Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma Business Wire
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cline Darren SEVP, CommercialJun 12Option Exercise29.1410,086293,91079,831Jun 14 06:31 PM
Cline Darren SEVP, CommercialJun 12Sale69.0012,054831,68869,863Jun 14 06:31 PM
SIEGALL CLAY BPresident and CEOJun 08Option Exercise11.0918,832208,847705,278Jun 12 07:34 PM
SIEGALL CLAY BPresident and CEOJun 08Sale65.1218,8321,226,341687,146Jun 12 07:34 PM
HIMES VAUGHN BChief Technical OfficerMay 31Option Exercise12.005,00060,000169,906Jun 04 07:11 PM
HIMES VAUGHN BChief Technical OfficerMay 31Sale58.475,000292,365164,906Jun 04 07:11 PM
Cline Darren SEVP, CommercialMay 09Option Exercise16.209,000145,79080,831May 11 07:59 PM
SIEGALL CLAY BPresident and CEOMay 09Option Exercise11.0918,832208,847694,922May 11 08:01 PM
SIEGALL CLAY BPresident and CEOMay 09Sale54.9718,8321,035,114687,146May 11 08:01 PM
Cline Darren SEVP, CommercialMay 09Sale55.339,000497,98371,831May 11 07:59 PM
BAKER BROS. ADVISORS LPDirectorMay 08Buy54.02126,3996,828,33945,825,986May 08 05:17 PM
BAKER BROS. ADVISORS LPDirectorMay 07Buy53.70129,7156,966,30545,699,587May 08 05:17 PM
BAKER BROS. ADVISORS LPDirectorMay 04Buy52.68204,53710,775,58245,569,872May 08 05:17 PM
Cline Darren SEVP, CommercialMay 03Sale53.814,000215,23871,831May 07 07:08 PM
BAKER BROS. ADVISORS LPDirectorMay 02Buy52.5769,9473,676,83645,365,335May 02 06:05 PM
BAKER BROS. ADVISORS LPDirectorMay 01Option Exercise10.0820,000201,60044,988,471May 02 06:05 PM
BAKER BROS. ADVISORS LPDirectorMay 01Buy51.36306,91715,764,73645,295,388May 02 06:05 PM
BAKER BROS. ADVISORS LPDirectorApr 30Buy51.06623,13631,816,92544,978,471May 02 06:05 PM
SIEGALL CLAY BPresident and CEOApr 09Option Exercise11.0918,832208,847705,978Apr 11 08:38 PM
SIEGALL CLAY BPresident and CEOApr 09Sale50.5218,832951,393687,146Apr 11 08:38 PM
DRACHMAN JONATHAN GCMO & EVP, R & DMar 20Option Exercise14.1531,039439,134201,973Mar 22 07:04 PM
HIMES VAUGHN BSee RemarksMar 15Option Exercise12.005,00060,000169,906Mar 19 07:35 PM
HIMES VAUGHN BSee RemarksMar 15Sale58.125,000290,604164,906Mar 19 07:35 PM
SIEGALL CLAY BPresident and CEOMar 09Option Exercise11.0918,832208,847701,214Mar 13 08:43 PM
SIEGALL CLAY BPresident and CEOMar 09Sale57.3218,8321,079,436687,146Mar 13 08:43 PM
DRACHMAN JONATHAN GCMO & EVP, R & DMar 05Option Exercise8.9610,45793,695178,134Mar 07 08:25 PM
DRACHMAN JONATHAN GCMO & EVP, R & DMar 05Sale52.8310,457552,452170,934Mar 07 08:25 PM
WELCH DANIEL GDirectorFeb 13Option Exercise9.3916,881158,46366,100Feb 15 09:21 PM
SIEGALL CLAY BPresident and CEOFeb 09Option Exercise11.0918,832208,847697,546Feb 13 08:19 PM
SIEGALL CLAY BPresident and CEOFeb 09Sale49.7518,832936,818687,146Feb 13 08:19 PM
BAKER BROS. ADVISORS LPDirectorFeb 01Buy52.003,846,153199,999,95644,355,335Feb 05 04:00 PM
SIEGALL CLAY BPresident and CEOJan 11Option Exercise11.0918,832208,847697,716Jan 16 08:08 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJan 11Option Exercise11.0619,416214,705170,934Jan 16 08:04 PM
SIEGALL CLAY BPresident and CEOJan 11Sale51.7118,832973,873687,146Jan 16 08:08 PM
SIEGALL CLAY BPresident and CEODec 11Option Exercise11.0918,832208,847698,933Dec 13 08:50 PM
SIEGALL CLAY BPresident and CEODec 11Sale55.4018,8321,043,329687,146Dec 13 08:50 PM
DOBMEIER ERICChief Operating OfficerDec 04Option Exercise32.006,165197,300121,153Dec 06 08:04 PM
DOBMEIER ERICChief Operating OfficerDec 04Sale58.753,729219,092117,424Dec 06 08:04 PM
HIMES VAUGHN BChief Technical OfficerNov 30Option Exercise12.1610,000121,573172,306Dec 04 07:54 PM
HIMES VAUGHN BChief Technical OfficerNov 30Sale59.9710,000599,729164,906Dec 04 07:54 PM
DOBMEIER ERICChief Operating OfficerNov 17Option Exercise26.1010,000261,000127,424Nov 17 08:45 PM
DOBMEIER ERICChief Operating OfficerNov 17Sale59.1310,000591,250117,424Nov 17 08:45 PM
DOBMEIER ERICChief Operating OfficerNov 16Option Exercise20.2315,400311,617125,913Nov 17 08:45 PM
DOBMEIER ERICChief Operating OfficerNov 16Sale57.9615,400892,637117,424Nov 17 08:45 PM
DOBMEIER ERICChief Operating OfficerNov 15Option Exercise15.469,600148,416127,024Nov 17 08:45 PM
LIPPMAN MARC EDirectorNov 15Sale58.073,000174,224132,050Nov 17 08:47 PM
DOBMEIER ERICChief Operating OfficerNov 15Sale57.809,600554,837117,424Nov 17 08:45 PM
SIEGALL CLAY BPresident and CEONov 10Option Exercise11.0918,832208,847704,255Nov 14 07:40 PM
SIEGALL CLAY BPresident and CEONov 10Sale58.0018,8321,092,193687,146Nov 14 07:40 PM
SIMPSON TODD EChief Financial OfficerNov 01Sale60.9139,3852,398,915178,992Nov 03 05:42 PM
SIEGALL CLAY BPresident and CEOOct 11Option Exercise11.0918,832208,847694,045Oct 13 08:58 PM
SIEGALL CLAY BPresident and CEOOct 11Sale61.1818,8321,152,234687,146Oct 13 08:58 PM
DRACHMAN JONATHAN GCMO & EVP, R & DOct 05Option Exercise11.5217,816205,253151,518Oct 10 06:42 PM
SIEGALL CLAY BPresident and CEOSep 26Option Exercise11.099,01799,999687,146Sep 28 06:15 PM
SIEGALL CLAY BPresident and CEOSep 11Option Exercise11.0918,832208,847695,246Sep 12 07:34 PM
SIEGALL CLAY BPresident and CEOSep 11Sale53.4918,8321,007,257678,129Sep 12 07:34 PM
HIMES VAUGHN BChief Technical OfficerSep 08Option Exercise11.2310,000112,329171,742Sep 12 07:32 PM
HIMES VAUGHN BChief Technical OfficerSep 08Sale53.2210,000532,190164,906Sep 12 07:32 PM
Cline Darren SEVP, CommercialSep 06Option Exercise15.9410,048160,11582,254Sep 08 07:32 PM
SIMPSON TODD EChief Financial OfficerSep 06Sale52.009,638501,176218,377Sep 08 07:34 PM
Cline Darren SEVP, CommercialSep 06Sale51.945,024260,96777,230Sep 08 07:32 PM
Cline Darren SEVP, CommercialAug 31Option Exercise18.462,90753,66379,775Sep 05 07:23 PM
DOBMEIER ERICChief Operating OfficerAug 31Option Exercise15.4625,000386,500142,424Sep 05 07:25 PM
DOBMEIER ERICChief Operating OfficerAug 31Sale52.2425,0001,305,893117,424Sep 05 07:25 PM
Cline Darren SEVP, CommercialAug 31Sale52.517,569397,46672,206Sep 05 07:23 PM
SIMPSON TODD EChief Financial OfficerAug 28Sale47.894,937236,455228,015Aug 30 07:27 PM
SIEGALL CLAY BPresident and CEOAug 28Sale47.8925,5061,221,597678,129Aug 30 07:25 PM
HIMES VAUGHN BChief Technical OfficerAug 28Sale47.896,377305,423164,906Aug 30 07:24 PM
DRACHMAN JONATHAN GCMO & EVP, R & DAug 28Sale47.898,502407,199133,702Aug 30 07:23 PM
DOBMEIER ERICChief Operating OfficerAug 28Sale47.895,343255,900117,424Aug 30 07:21 PM
Cline Darren SEVP, CommercialAug 28Sale47.891,78885,63576,868Aug 30 07:18 PM
DRACHMAN JONATHAN GCMO & EVP, R & DAug 24Option Exercise10.2910,000102,900152,204Aug 25 07:52 PM
DRACHMAN JONATHAN GCMO & EVP, R & DAug 24Sale47.5410,000475,414142,204Aug 25 07:52 PM
Cline Darren SEVP, CommercialAug 07Option Exercise18.466,000110,76067,656Aug 09 06:52 PM
SIEGALL CLAY BPresident and CEOAug 07Option Exercise10.2910,413107,150646,848Aug 09 06:58 PM
SIEGALL CLAY BPresident and CEOAug 07Sale48.9110,413509,300636,435Aug 09 06:58 PM
Cline Darren SEVP, CommercialAug 07Sale49.196,000295,11061,656Aug 09 06:52 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJul 27Option Exercise10.2910,000102,900125,204Jul 31 07:15 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJul 27Sale54.5410,000545,361115,204Jul 31 07:15 PM
SIEGALL CLAY BPresident and CEOJul 05Option Exercise10.2910,423107,253644,629Jul 07 07:20 PM
SIEGALL CLAY BPresident and CEOJul 05Sale51.9810,423541,807636,435Jul 07 07:20 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJun 22Option Exercise10.2910,000102,900125,204Jun 26 06:25 PM
DRACHMAN JONATHAN GCMO & EVP, R & DJun 22Sale64.0110,000640,058115,204Jun 26 06:25 PM